Oncotarget | Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

“MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.”

BUFFALO, NY- November 29, 2022 – A new review was published in Oncotarget’s Volume 13 on November 17, 2022, entitled, “Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more.”

Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies.

In this new review paper, researchers Masahiko Shibata, Kotaro Nanno, Daigo Yoshimori, Takahiro Nakajima, Makoto Takada, Takashi Yazawa, Kousaku Mimura, Norio Inoue, Takafumi Watanabe, Kazunoshin Tachibana, Satoshi Muto, Tomoyuki Momma, Yoshiyuki Suzuki, Koji Kono, Shungo Endo, and Seiichi Takenoshita from Fukushima Medical University, Aizu Chuo Hospital, Aizu Oncology Consortium, Nippon Medical School, and Bange Kousei General Hospital reviewed the perspective of MDSCs with emerging evidence.

“Here, we review the following: the phenotypes and origins of MDSCs; the mechanisms of immunosuppression by MDSCs; MDSC functions in the TME; MDSCs in benign disorders and physiology; and consideration of MDSC manipulation in cancer treatment.”

Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.

ICI therapies have been developed and demonstrated surprising outcomes in many types of cancer. However, the effects of ICIs are not universal or uniformal in all cancer patients, and emerging evidence has indicated that MDSCs are a crucial target to overcome this important issue with a growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are under exploration, some of which have been used in clinical trials. 

“More studies are required for the development of more effective strategies against MDSCs.”
 

DOI: https://doi.org/10.18632/oncotarget.28303 

Correspondence to: Masahiko Shibata

Email: [email protected] 

Keywords: MDSC, immunosuppression, Treg, TAM, cancer
 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

• Twitter – https://twitter.com/Oncotarget 
• Facebook – https://www.facebook.com/Oncotarget 
• YouTube – www.youtube.com/c/OncotargetYouTube 
• Instagram – https://www.instagram.com/oncotargetjrnl/ 
• LinkedIn – https://www.linkedin.com/company/oncotarget/ 
• Pinterest – https://www.pinterest.com/oncotarget/ 
• LabTube – https://www.labtube.tv/channel/MTY5OA
• SoundCloud – https://soundcloud.com/oncotarget

For media inquiries, please contact: [email protected].

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###